Jun 23, 2022
Galderma recently made national headlines with a new neurotoxin that promises rapid onset and long duration up to 6 months — and while that may sound too good to be true, the data comes directly from two phase III clinical studies.
If that were the only news Galderma CEO Flemming Ørnskov had for us, it would be...
Jun 14, 2022
It’s one thing to say you want to do a better job in aesthetic medicine, to enhance your offerings, and “be part of something bigger.” It’s another thing entirely to actually achieve it.
Drawing on experience gained as an executive at Lumenis, Biolase, Allergan and Medicis, Athenix CEO James Haefner set out...
Jun 2, 2022
"A lot of what's happening in the world of industry and aesthetics happens here." Welcome to the Aesthetics Innovation Summit in San Diego, where that quote from Dr. Steve Dayan has never been more true. For while "innovation" as a word can tend toward overuse, at AIS we find factual transformation and metamorphosis in...